Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
06. November 2019 16:15 ET
|
Bellicum Pharmaceuticals, Inc.
Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to...
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
31. Oktober 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
30. Oktober 2019 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30. September 2019 16:07 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30. August 2019 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
28. August 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
21. August 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
16. August 2019 10:52 ET
|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
16. August 2019 08:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
15. August 2019 17:37 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...